Filtered By:
Procedure: Hemodialysis
Therapy: Dialysis

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 299 results found since Jan 2013.

Dialysis
More than 400 000 persons in the United States are currently receiving maintenance dialysis as life-sustaining treatment for end-stage renal disease (ESRD), with more than 90% receiving in-center hemodialysis. Mortality rates in the ESRD population in the United States remain extremely high (18%-20% per year) despite a slight downward trend during the past 2 to 3 years. Most deaths among patients with ESRD are due to cardiovascular disease, with exceptionally high rates, particularly on an age-adjusted basis, of heart failure, stroke, and sudden death. In fact, sudden death accounts for roughly 1 in 4 deaths among patien...
Source: JAMA Internal Medicine - April 27, 2015 Category: Internal Medicine Source Type: research

SuO001 * RISK OF ISCHAEMIC STROKE FOR INCIDENT PATIENTS TREATED WITH PERITONEAL DIALYSIS VERSUS HAEMODIALYSIS
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Stack, A. G., Elsayed, M. E., Sharif, M. U., Clarke Moloney, M., Ferguson, J. P. Tags: DIALYSIS CARDIOVASCULAR PATHOPHYSIOLOGY Source Type: research

Fp721 * rising global incidence of hemorrhagic stroke in hemodialysis
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Power, A., Usvyat, L., Marcelli, D., Canaud, B., Guinsburg, A., Marelli, C., Pusey, C., Levin, N., Kotanko, P., MONDO Initiative Tags: DIALYSIS. EPIDEMIOLOGY, OUTCOME RESEARCH, HEALTH SERVICES RESEARCH - 1 Source Type: research

Sp686 * contrasting worldwide trends of stroke incidence in hemodialysis - cause for concern
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Power, A., Usvyat, L., Pusey, C., Canaud, B., Marcelli, D., Guinsburg, A., Marelli, C., Levin, N., Kotanko, P., and the MONDO Initiative Tags: DIALYSIS. EPIDEMIOLOGY, OUTCOME RESEARCH, HEALTH SERVICES RESEARCH - 2 Source Type: research

Dose-Finding Study of Rivaroxaban in Hemodialysis Patients
Conclusions A 10-mg dose of rivaroxaban in hemodialysis patients without residual kidney function results in drug exposure similar as published for 20mg in healthy volunteers. Rivaroxaban is not eliminated by dialysis. There is no accumulation after multiple daily dosing. The efficacy and safety of rivaroxaban in hemodialysis patients should be the subject of a large randomized trial.
Source: American Journal of Kidney Diseases - June 22, 2015 Category: Urology & Nephrology Source Type: research

Dabigatran treatment simulation in patients undergoing maintenance haemodialysis.
This study simulated the dose-exposure relationship of dabigatran in patients undergoing haemodialysis. Dabigatran exposure was modelled at once- and twice-daily doses of 75 mg, 110 mg and 150 mg and at variations in non-renal clearance and dialysis settings. Resultant dose exposure (area under the curve [AUC]) was compared with values simulated from typical patients in the RE-LY® trial (based on a previously characterised pharmacometric model). In this simulation, all twice-daily dosages resulted in exposures above those simulated from typical RE-LY patients (1.5- to 3.3-fold increase in AUC) and thus may not be optimal ...
Source: Thrombosis and Haemostasis - October 15, 2015 Category: Hematology Authors: Liesenfeld KH, Clemens A, Kreuzer J, Brueckmann M, Schulze F Tags: Thromb Haemost Source Type: research

Timing of Dialysis Initiation, Duration and Frequency of Hemodialysis Sessions, and Membrane Flux: A Systematic Review for a KDOQI Clinical Practice Guideline
Conclusions Limited data indicate that earlier dialysis therapy initiation and more frequent and longer hemodialysis did not improve clinical outcomes compared to conventional hemodialysis.
Source: American Journal of Kidney Diseases - October 21, 2015 Category: Urology & Nephrology Source Type: research

Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients
Conclusions In incident HD patients, ferumoxytol showed similar short- to mid-term safety profiles with regard to cardiovascular, infectious and mortality outcomes compared with the more commonly used intravenous iron formulations IS and FG.
Source: Nephrology Dialysis Transplantation - November 23, 2015 Category: Urology & Nephrology Authors: Airy, M., Mandayam, S., Mitani, A. A., Chang, T. I., Ding, V. Y., Brookhart, M. A., Goldstein, B. A., Winkelmayer, W. C. Tags: Intra- and extracorporeal treatments of kidney failure Source Type: research

Safety of warfarin therapy in chronic hemodialysis patients: a prospective cohort study
Conclusion The results of this study suggested that warfarin use by HD patients might not be harmful in chronic state, while the safety for the initiation of warfarin therapy in HD patients remained to be determined.
Source: Clinical and Experimental Nephrology - December 1, 2015 Category: Urology & Nephrology Source Type: research

COGNITIVE-HD study: protocol of an observational study of neurocognitive functioning and association with clinical outcomes in adults with end-stage kidney disease treated with haemodialysis
Introduction The prevalence of cognitive impairment may be increased in adults with end-stage kidney disease compared with the general population. However, the specific patterns of cognitive impairment and association of cognitive dysfunction with activities of daily living and clinical outcomes (including withdrawal from treatment) among haemodialysis patients remain incompletely understood. The COGNITIVE impairment in adults with end-stage kidney disease treated with HemoDialysis (COGNITIVE-HD) study aims to characterise the age-adjusted and education-adjusted patterns of cognitive impairment (using comprehensive testing...
Source: BMJ Open - December 9, 2015 Category: Journals (General) Authors: Palmer, S. C., Ruospo, M., Barulli, M. R., Iurillo, A., Saglimbene, V., Natale, P., Gargano, L., Murgo, A. M., Loy, C., van Zwieten, A., Wong, G., Tortelli, R., Craig, J. C., Johnson, D. W., Tonelli, M., Hegbrant, J., Wollheim, C., Logroscino, G., Strippo Tags: Open access, Epidemiology, Neurology Protocol Source Type: research

Early versus delayed erythropoietin for the anaemia of end-stage kidney disease.
CONCLUSIONS: We found no evidence to assess the benefits and harms of early versus delayed EPO for the anaemia of ESKD. PMID: 26671531 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - December 16, 2015 Category: Journals (General) Authors: Coronado Daza J, Martí-Carvajal AJ, Ariza García A, Rodelo Ceballos J, Yomayusa González N, Páez-Canro C, Loza Munárriz C, Urrútia G Tags: Cochrane Database Syst Rev Source Type: research

Valacyclovir and Acyclovir Neurotoxicity With Status Epilepticus
We present the case of a 52-year-old man with hypertension, diastolic congestive heart failure, end-stage renal disease on hemodialysis 3 times a week and a remote history of a hemorrhagic stroke who presented to the emergency department with a vesicular rash on his left arm. The rash was observed to be in a dermatomal distribution, and a diagnosis of herpes zoster was made. The patient was discharged home on valacyclovir 1 g 3 times a day for a duration of 7 days. The patient took 2 doses of valacyclovir before presenting to the hospital again with irritability and hallucinations. Over the next several days, the patient's...
Source: American Journal of Therapeutics - January 1, 2016 Category: Drugs & Pharmacology Tags: Case Reports Source Type: research

Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis
The 4D (Die Deutsche Diabetes Dialyse) Study was a randomized, double-blind trial comparing 4 years of treatment with atorvastatin to placebo in 1255 hemodialysis patients with type 2 diabetes. The primary end point of cardiovascular events (cardiac death, myocardial infarction, and stroke) was non-significantly reduced by 8%. However, long-term effects remained uncertain. Therefore, surviving patients were invited to a follow-up survey done by questionnaire. Post-trial statin therapy was at nephrologist discretion, and outcomes were centrally adjudicated and analyzed by intention to treat and time to first event in the or...
Source: Kidney International - February 17, 2016 Category: Urology & Nephrology Authors: Vera Krane, Kay-Renke Schmidt, Lena J. Gutjahr-Lengsfeld, Johannes F.E. Mann, Winfried März, Florian Swoboda, Christoph Wanner, 4D Study Investigators (the German Diabetes and Dialysis Study Investigators) Tags: Clinical Trial Source Type: research

Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study
Background: Stroke prevention in dialysis-dependent patients with atrial fibrillation (AF) is an unresolved clinical dilemma. Indeed, no randomized controlled trial evaluating the efficacy and safety of oral anticoagulants in this population, has been conducted so far. Observational research on the use of warfarin in patients on dialysis has shown conflicting results. This uncertainty is mirrored by the wide variations in warfarin prescription patterns across centers. We sought to evaluate the association between the use of vitamin K antagonists (VKAs) and mortality among hemodialysis patient with AF and to assess potentia...
Source: American Journal of Nephrology - September 6, 2016 Category: Neurology Source Type: research

Cognitive Impairment in Advanced Chronic Kidney Disease: The Canadian Frailty Observation and Interventions Trial.
CONCLUSIONS: Our study uncovered a high rate of unrecognized cognitive impairment in an advanced CKD population. This impairment is global, affecting all aspects of cognition and is likely vascular in nature. The longitudinal trajectory of cognitive function and its effect on dialysis decision-making and outcomes deserves further study. PMID: 27798938 [PubMed - as supplied by publisher]
Source: American Journal of Nephrology - October 31, 2016 Category: Urology & Nephrology Authors: Foster R, Walker S, Brar R, Hiebert B, Komenda P, Rigatto C, Storsley L, Prasad B, Bohm C, Tangri N Tags: Am J Nephrol Source Type: research